Today it was reported that a Director at Progenics (PGNX), Peter J. Crowley, exercised options to buy 50,000 PGNX shares at $5.34 a share, for a total transaction value of $267.3K. The options were close to expired and Peter J. Crowley retained stocks.
See today’s analyst top recommended stocks >>
Based on Progenics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $4.28 million and GAAP net loss of $18.74 million. In comparison, last year the company earned revenue of $3.19 million and had a GAAP net loss of $13.42 million. Currently, Progenics has an average volume of 923.2K.
Starting in July 2018, PGNX received 14 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.